Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Tumour Biol ; 36(3): 1653-9, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25371071

ABSTRACT

Matrine, a natural product, has been demonstrated to be a promising chemotherapeutic drug for some cancers. Using flow cytometric analysis of the cell cycle and apoptosis, we found that matrine inhibited the proliferation and induced apoptosis in the human osteosarcoma (OS) cell lines MG63, HOS, U2OS, and SAOS2 in vitro in a dose-dependent manner. We therefore assessed the role of the serine/threonine kinase Akt in the regulation of matrine-mediated cell growth inhibition and apoptosis induction in human OS cell lines. After treatment for 48 h, matrine induced G0/G1-stage cell cycle arrest in MG63, U2OS, and SAOS2 cells associated with an increase in the expression of p27(Kip1) and a decrease in the expression of Akt, glycogen synthase kinase 3 (GSK3)-ß (Ser9), and cyclin D1. Furthermore, the pro-apoptotic factor Bax was upregulated. Overall, our findings suggest that matrine may be an effective anti-osteosarcoma drug due to its ability to inhibit proliferation and induce apoptosis in OS cells, possibly through the involvement of Akt signaling.


Subject(s)
Alkaloids/pharmacology , Apoptosis/drug effects , Bone Neoplasms/drug therapy , Osteosarcoma/drug therapy , Proto-Oncogene Proteins c-akt/metabolism , Quinolizines/pharmacology , Signal Transduction/drug effects , Bone Neoplasms/metabolism , Bone Neoplasms/pathology , Cell Line, Tumor , Cell Proliferation/drug effects , Cyclin D1/metabolism , Cyclin-Dependent Kinase Inhibitor p27/metabolism , G1 Phase Cell Cycle Checkpoints/drug effects , Glycogen Synthase Kinase 3/metabolism , Glycogen Synthase Kinase 3 beta , Humans , Osteosarcoma/metabolism , Osteosarcoma/pathology , Resting Phase, Cell Cycle/drug effects , bcl-2-Associated X Protein/metabolism , Matrines
2.
Neurosci Lett ; 560: 51-6, 2014 Feb 07.
Article in English | MEDLINE | ID: mdl-24316441

ABSTRACT

Spinal cord injury (SCI) is a serious clinical situation without any effective therapy to date. Traumatic SCI triggers a complex pathological process including inflammatory response and glial scar formation. In this study, we demonstrated that curcumin, a natural product which functions as an anti-inflammatory agent, inhibited the activation of signal transducer and activator of transcription-3 and NF-kappa B in the injured spinal cord. Curcumin treatment greatly reduced the astrogliosis in SCI mice and significantly decreased the expression of IL-1ß and NO, as well as the number of Iba1(+) inflammatory cells at the lesion site. Notably, more residual axons and neurons were protected and significantly improved functional recovery was observed in the curcumin-treated mice, compared to the mice without curcumin treatment. These findings indicate that curcumin promotes spinal cord repair through inhibiting glial scar formation and inflammation and suggests the therapeutic potential of curcumin for SCI.


Subject(s)
Cicatrix/drug therapy , Curcumin/pharmacology , Neuroglia/drug effects , Neuroprotective Agents/pharmacology , Spinal Cord Injuries/drug therapy , Animals , Cicatrix/immunology , Cicatrix/pathology , Curcumin/therapeutic use , Female , Gliosis , Inflammation/drug therapy , Inflammation/immunology , Inflammation/pathology , Interleukin-1beta/metabolism , Mice, Inbred BALB C , NF-kappa B/metabolism , Neuroglia/pathology , Neurons/drug effects , Neurons/pathology , Neuroprotective Agents/therapeutic use , Nitric Oxide/metabolism , STAT3 Transcription Factor/antagonists & inhibitors , Spinal Cord/drug effects , Spinal Cord/immunology , Spinal Cord/metabolism , Spinal Cord/pathology , Spinal Cord Injuries/immunology , Spinal Cord Injuries/metabolism , Spinal Cord Injuries/pathology
3.
Mol Cell Biochem ; 382(1-2): 243-52, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23812885

ABSTRACT

We previously demonstrated that gambogic acid (GA) is a promising chemotherapeutic compound for human osteosarcoma treatment. The aim of this study was to detect whether the combination of lower-dose GA (0.3 mg/L) and cisplatin (CDDP) (1 mg/L) could perform a synergistic effect on inhibiting tumor in four osteosarcoma cell lines. Our results showed that the combination between GA at lower dose and CDDP significantly exerts a synergistic effect on inhibiting the cellular viability in MG63, HOS, and U2OS cells. In contrast, an antagonistic character was detected in SAOS2 cells exposed to the combined use of lower-dose GA (0.3 mg/L) and CDDP (1 mg/L). Then, analysis of cell cycle showed the combination of both drugs significantly induced the G2/M phase arrest, without any difference relative to GA treatment alone, in MG63 cells. Flow-cytometric analysis of cell apoptosis displayed that the apoptotic rate in the combination group is higher than that in GA treatment alone in MG63, HOS, and U2OS cells. The combined use of both drugs had no effect on mitochondrial membrane potential, but promoted the apoptosis-inducing function through triggering of CDDP in the three cell lines. By measurement of mitochondrial membrane potential, the activity of caspase-3 and the expressions of caspase-8 and caspase-9, it was showed that the apoptosis-promoting effect of the combined use of both drugs could be dependent on the death receptor apoptosis pathway, not dependent on the mitochondria apoptosis mechanism. This research, for the first time, demonstrates that GA could increase the chemotherapeutic effect of CDDP in human osteosarcoma treatment through inducing the cell cycle arrest and promoting cell apoptosis.


Subject(s)
Apoptosis/drug effects , Cisplatin/pharmacology , Mitochondria/metabolism , Osteosarcoma/pathology , Signal Transduction/drug effects , Xanthones/pharmacology , Apoptosis Regulatory Proteins/metabolism , Caspase 8/metabolism , Caspase 9/metabolism , Cell Line, Tumor , Cell Survival/drug effects , Drug Synergism , G2 Phase Cell Cycle Checkpoints/drug effects , Humans , Membrane Potential, Mitochondrial/drug effects , Mitochondria/drug effects , Osteosarcoma/enzymology
SELECTION OF CITATIONS
SEARCH DETAIL